Poster Hall
Sponsored by Novartis Medical Affairs
What's Hot
View all perspectives
Dr. John Cush RheumNow
1 month ago
Apremilast Benefits and Risks in PsA
Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24.
https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO
Dr. John Cush RheumNow
1 month ago
#ACR24 BEST Abstracts from Day 2
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.
https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah
Dr. John Cush RheumNow
1 month ago
#ACR24 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN
Dr. John Cush RheumNow
1 month ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
1 month ago
Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA
For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush RheumNow
1 month ago
RheumNow Day 2 Recap: #ACR24 Highlights
Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush RheumNow
1 month ago
RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh
Dr. John Cush RheumNow
1 month ago
Transplant-free Survival Predictors in Idiopathic Inflammatory Myopathies-ILD
Dr. Gaby Martinez discusses abstract 0333, Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease, presented at #ACR24.… https://t.co/3TSZ6PvZsD https://t.co/DLdzzfXhhp
Dr. John Cush RheumNow
1 month ago
Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis
Dr. Antoni Chan interviews Dr. Catherine Bakewell on the Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis, at #ACR24.
https://t.co/iCwNsuo7xz
@synovialjoints https://t.co/Tjx3CE27TK
Dr. John Cush RheumNow
1 month ago
PsA Potpourri
Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24
https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd
Dr. John Cush RheumNow
1 month ago
JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P
Dr. John Cush RheumNow
1 month ago
Where there’s smoke, there’s flare: how pollution fuels RA The World Health Organisation (WHO) has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 (1, 2)… https://t.co/hmXPa492Qr https://t.co/BBClCplk8Z
Dr. John Cush RheumNow
1 month ago
Say Goodbye to Methotrexate in PMR?
Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24
https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq
Dr. John Cush RheumNow
1 month ago
Health Literacy: the forgotten social determinant of health?
Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/15gvQxZHNN https://t.co/VqCjZY4tYI
